Eagle Asset Management Inc. Sells 370 Shares of Guardant Health, Inc. (NASDAQ:GH)

Eagle Asset Management Inc. decreased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 0.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 423,071 shares of the company’s stock after selling 370 shares during the quarter. Eagle Asset Management Inc.’s holdings in Guardant Health were worth $52,541,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. FMR LLC lifted its position in Guardant Health by 28.3% during the first quarter. FMR LLC now owns 464,612 shares of the company’s stock worth $35,636,000 after acquiring an additional 102,483 shares during the last quarter. First Trust Advisors LP increased its stake in shares of Guardant Health by 0.4% during the first quarter. First Trust Advisors LP now owns 71,871 shares of the company’s stock worth $5,513,000 after purchasing an additional 264 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Guardant Health by 5.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 197,399 shares of the company’s stock worth $25,435,000 after purchasing an additional 11,019 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Guardant Health by 131.0% in the 1st quarter. Victory Capital Management Inc. now owns 71,327 shares of the company’s stock valued at $10,888,000 after purchasing an additional 40,446 shares during the period. Finally, Commonwealth Equity Services LLC grew its holdings in Guardant Health by 8.8% in the 1st quarter. Commonwealth Equity Services LLC now owns 5,922 shares of the company’s stock valued at $903,000 after buying an additional 478 shares in the last quarter. 87.58% of the stock is owned by hedge funds and other institutional investors.

In other Guardant Health news, Director Stanley J. Meresman sold 4,934 shares of the stock in a transaction dated Monday, July 12th. The shares were sold at an average price of $124.27, for a total value of $613,148.18. Following the completion of the sale, the director now owns 8,993 shares in the company, valued at approximately $1,117,560.11. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ian T. Clark sold 10,559 shares of the company’s stock in a transaction that occurred on Tuesday, June 29th. The shares were sold at an average price of $130.00, for a total value of $1,372,670.00. Following the completion of the transaction, the director now directly owns 5,719 shares of the company’s stock, valued at $743,470. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,361 shares of company stock valued at $3,190,158. Corporate insiders own 5.80% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. William Blair reissued a “buy” rating on shares of Guardant Health in a research report on Thursday, May 27th. Zacks Investment Research upgraded shares of Guardant Health from a “sell” rating to a “hold” rating in a research report on Monday, August 16th. The Goldman Sachs Group assumed coverage on Guardant Health in a report on Thursday, June 3rd. They issued a “buy” rating and a $160.00 price objective for the company. Raymond James started coverage on Guardant Health in a research note on Tuesday, June 15th. They issued a “market perform” rating for the company. Finally, Wells Fargo & Company boosted their target price on shares of Guardant Health from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, June 21st. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $164.00.

GH stock opened at $129.16 on Tuesday. Guardant Health, Inc. has a 1-year low of $96.66 and a 1-year high of $181.07. The company has a current ratio of 19.57, a quick ratio of 19.30 and a debt-to-equity ratio of 1.44. The stock has a 50-day moving average price of $117.13 and a 200-day moving average price of $128.75. The firm has a market cap of $13.08 billion, a PE ratio of -34.26 and a beta of 0.51.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, August 5th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.87) by ($0.09). Guardant Health had a negative net margin of 116.99% and a negative return on equity of 37.35%. The company had revenue of $92.10 million for the quarter, compared to analyst estimates of $84.63 million. On average, analysts forecast that Guardant Health, Inc. will post -3.98 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.

Further Reading: Stocks Increasing Dividends

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.